TY - JOUR
T1 - Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
AU - Shirasawa, Masayuki
AU - Yoshida, Tatsuya
AU - Matsutani, Takaji
AU - Takeyasu, Yuki
AU - Goto, Naoko
AU - Yagishita, Shigehiro
AU - Kitano, Shigehisa
AU - Kuroda, Hiroaki
AU - Hida, Toyoaki
AU - Kurata, Takayasu
AU - Ohe, Yuichiro
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT. Forty patients treated with CRT were included. The diversity and usage of TCR beta variable chains (TRBV) and 14 junctional chains (TRBJ) were significantly and positively correlated before and after CRT. Regarding the DE50, the progression-free survival (PFS) of patients with DE50High before CRT was significantly greater than that of those with DE50Low (NR vs. NR months, HR 0.17, p = 0.01). The diversity of TCR repertoire might more accurately predict the efficacy of CRT followed by durvalumab therapy.
AB - Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT. Forty patients treated with CRT were included. The diversity and usage of TCR beta variable chains (TRBV) and 14 junctional chains (TRBJ) were significantly and positively correlated before and after CRT. Regarding the DE50, the progression-free survival (PFS) of patients with DE50High before CRT was significantly greater than that of those with DE50Low (NR vs. NR months, HR 0.17, p = 0.01). The diversity of TCR repertoire might more accurately predict the efficacy of CRT followed by durvalumab therapy.
UR - https://www.scopus.com/pages/publications/85217863184
U2 - 10.1038/s41698-024-00781-w
DO - 10.1038/s41698-024-00781-w
M3 - 記事
AN - SCOPUS:85217863184
SN - 2397-768X
VL - 9
JO - npj Precision Oncology
JF - npj Precision Oncology
IS - 1
M1 - 17
ER -
